 |
|
Relationship Between Adherence to Evidence-Based Pharmacotherapy and Long-term Mortality After Acute Myocardial Infarction
Jeppe N. Rasmussen, MD;
Alice Chong, BSc;
David A. Alter, MD, PhD, FRCPC
JAMA. 2007;297:177-186.
Context The extent to which drug adherence may affect survival remains unclear, in part because mortality differences may be attributable to "healthy adherer" behavioral attributes more so than to pharmacological benefits.
Objective To explore the relationship between drug adherence and mortality in survivors of acute myocardial infarction (AMI).
Design, Setting, and Participants Population-based, observational, longitudinal study of 31 455 elderly AMI survivors between 1999 and 2003 in Ontario. All patients filled a prescription for statins,  -blockers, or calcium channel blockers, with the latter drug considered a control given the absence of clinical trial–proven survival benefits.
Main Outcome Measures Patient adherence was subdivided a priori into 3 categories—high (proportion of days covered,  80%), intermediate (proportion of days covered, 40%-79%), and low (proportion of days covered, <40%)—and compared with long-term mortality (median of 2.4 years of follow-up) using multivariable survival models (and propensity analyses) adjusted for sociodemographic factors, illness severity, comorbidities, and concomitant use of evidence-based therapies.
Results Among statin users, compared with their high-adherence counterparts, the risk of mortality was greatest for low adherers (deaths in 261/1071 (24%) vs 2310/14 345 (16%); adjusted hazard ratio, 1.25; 95% confidence interval, 1.09-1.42; P = .001) and was intermediary for intermediate adherers (deaths in 472/2407 (20%); adjusted hazard ratio, 1.12; 95% confidence interval, 1.01-1.25; P = .03). A similar but less pronounced dose-response–type adherence-mortality association was observed for -blockers. Mortality was not associated with adherence to calcium channel blockers. Moreover, sensitivity analyses demonstrated no relationships between drug adherence and cancer-related admissions, outcomes for which biological plausibility do not exist.
Conclusion The long-term survival advantages associated with improved drug adherence after AMI appear to be class-specific, suggesting that adherence outcome benefits are mediated by drug effects and do not merely reflect an epiphenomenon of "healthy adherer" behavioral attributes.
Author Affiliations: Institute of Clinical Evaluative Sciences (Drs Rasmussen and Alter and Ms Chong), Clinical Epidemiology Unit, Sunnybrook Health Sciences Centre (Dr Alter), Division of Cardiology and the Li Ka Shing Knowledge Institute of St Michael's Hospital (Dr Alter), and Departments of Medicine and Health Policy, Management, and Evaluation, University of Toronto (Dr Alter), Toronto, Ontario; and National Institute of Public Health, Copenhagen, Denmark (Dr Rasmussen).
RELATED LETTERS
Performance Measures and Outcomes for Patients Hospitalized With Heart Failure
Mehdi H. Shishehbor and David Litaker
JAMA. 2007;297(14):1547.
EXTRACT
| FULL TEXT
Mortality and Adherence to Pharmacotherapy After Acute Myocardial Infarction
Kapil Parakh, David E. Bush, Roy C. Ziegelstein, Brett D. Thombs, and James A. Fauerbach
JAMA. 2007;297(17):1877.
EXTRACT
| FULL TEXT
Mortality and Adherence to Pharmacotherapy After Acute Myocardial Infarction
Mitsuyo Kinjo, Kiyoshi Kinjo, Isao Iwata, and Soko Setoguchi
JAMA. 2007;297(17):1877-1878.
EXTRACT
| FULL TEXT
Mortality and Adherence to Pharmacotherapy After Acute Myocardial Infarction—Reply
Jeppe N. Rasmussen and David A. Alter
JAMA. 2007;297(17):1878.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Outcomes Research: Generating Evidence for Best Practice and Policies
Krumholz
Circulation 2008;118:309-318.
FULL TEXT
Lipid Levels in the Post-Acute Coronary Syndrome Setting: Destabilizing Another Myth?
Miller
J Am Coll Cardiol 2008;51:1446-1447.
FULL TEXT
Improving the Quality of Measurement and Evaluation in Quality Improvement Efforts
Pronovost et al.
American Journal of Medical Quality 2008;23:143-146.
The year in atherothrombosis.
Sanz et al.
J Am Coll Cardiol 2008;51:944-955.
FULL TEXT
Factors Related to Adherence to Statin Therapy
McGinnis et al.
The Annals of Pharmacotherapy 2007;41:1805-1811.
ABSTRACT
| FULL TEXT
The Year in Non ST-Segment Elevation Acute Coronary Syndrome
Giugliano and Braunwald
J Am Coll Cardiol 2007;50:1386-1395.
FULL TEXT
Self-reported Medication Adherence and Cardiovascular Events in Patients With Stable Coronary Heart Disease: The Heart and Soul Study
Gehi et al.
Arch Intern Med 2007;167:1798-1803.
ABSTRACT
| FULL TEXT
ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) Developed in Collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons Endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine
Anderson et al.
J Am Coll Cardiol 2007;50:e1-e157.
FULL TEXT
Persistent Use of Evidence-Based Pharmacotherapy in Heart Failure Is Associated With Improved Outcomes
Gislason et al.
Circulation 2007;116:737-744.
ABSTRACT
| FULL TEXT
Mortality and Adherence to Pharmacotherapy After Acute Myocardial Infarction
Parakh et al.
JAMA 2007;297:1877-1877.
FULL TEXT
Mortality and Adherence to Pharmacotherapy After Acute Myocardial Infarction
Kinjo et al.
JAMA 2007;297:1877-1878.
FULL TEXT
Performance Measures and Outcomes for Patients Hospitalized With Heart Failure
Shishehbor and Litaker
JAMA 2007;297:1547-1547.
FULL TEXT
Adherence to drug treatments prolongs survival after heart attack
BMJ 2007;334:118-118.
FULL TEXT
|
